Optimizing endocrine therapy in premenopausal ER-positive breast cancer patients.
Ruddy
Kathryn J
KJ
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachussetts, USA.
Partridge
Ann J
AJ
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D005260:Female; D006801:Humans; D010053:Ovary / Q000187:drug effects*; D017697:Premenopause; D011960:Receptors, Estrogen / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen; D013629:Tamoxifen